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ARTICLE
Patient and public perspectives on cell and gene
therapies: a systematic review
Olalekan Lee Aiyegbusi 1,2,3,4,11✉, Karen Macpherson5,11, Lauren Elston6, Susan Myles6, Jennifer Washington6,
Nisha Sungum4,7, Mark Briggs8, Philip N. Newsome2,3,4,9,10 & Melanie J. Calvert 1,2,3,4
Cell and gene therapies offer opportunities for treating disease with potential to restore
function, and cure disease. However, they are not without risk and pose complex logistical,
economic, ethical and social challenges for health systems. Here we report our systematic
review of the current evidence on patient and public knowledge and perspectives of cell and
gene therapies, to inform future research, education and awareness raising activities. We
screened 10,735 titles and abstracts, and evaluated the full texts of 151 publications. The final
selection was 35 publications. Four themes were generated from the narrative synthesis of
the study findings namely: (1) Knowledge and understanding of cell and gene therapies, (2)
Acceptance of cell and gene therapies (3) Understanding of risk and benefits of therapy, and
(4) Information needs and current sources of information. As potential funders or future
recipients, it is important that the public and patients are aware of these therapies, under-
stand the issues involved, and can contribute to the debate. This review highlights the need
for appropriate patient and public education on the various aspects of cell and gene therapies.
High quality studies exploring patient and public opinions and experiences of cell and gene
therapy are required. Patient and public perceptions of these therapies, alongside evidence of
clinical and cost-effectiveness, will be central to their uptake and use.
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Over the last decade, new cell, gene and tissue-engineeredtherapies have been developed to treat various cancers,inherited diseases and some chronic conditions1. They
offer opportunities for the treatment of disease and injury, to
restore function, and in some cases offer cures1–4.
These therapies are approved and regulated in the US by the
Center for Biologics Evaluation and Research5 and in Europe by
the European Medicines Agency (EMA)6. The EMA refers to cell
and gene therapies along with tissue-engineered medicines as
Advanced Therapy Medicinal Products (ATMPs)7.
The provision of these therapies present logistical and delivery
challenges for health systems globally8. In addition, there are
complex social, ethical, health and economic issues to navigate
which require the input of patients, carers and the public to
ensure successful resolution9,10. A high level of engagement,
awareness and understanding among patients and the public will
ensure their vital contribution to policy debates and enhance their
ability to make informed decisions about participation in trials
and routine administration of cell and gene therapies11. It is
therefore crucial that health systems, regulatory bodies and
researchers are aware of the knowledge and perspectives of
patients and the public as this insight may guide information
provision, patient and public involvement (PPI) activities and
inform the development and delivery of targeted educational
interventions.
In this work, utilising systematic approaches, we summarise
and discuss the current evidence on patient and public opinions
on cell and gene therapies: their acceptance of these therapies,
their understanding of the associated risks and benefits, and their
views regarding reimbursement. In addition, we explore the
potential influences on their views and highlight future priority
areas for research. We focus on therapies we anticipate will gain
increased licensing within the next decade. For this reason, we
exclude studies that dealt solely with embryonic stem-cell therapy
or germline gene therapy due to the complex legal and ethical
issues associated with these therapies. We provide descriptions of
the cell, gene and tissue-engineered therapies in the Supple-
mentary Table 1.
Results
The searches returned 11,786 bibliographic records. After
removing 1051 duplicates, 10,735 titles and abstracts were
screened. Of these, 151 articles were taken forward and following
full-text review, 33 papers were selected. Two publications were
identified following a hand search of reference lists giving a total
of 35 studies (Supplementary Fig. 1). The article selections by K.
M. and O.L.A. fully matched at the screening stage. At the full-
text review, the reviewers had to discuss 5% of the articles further
before making a final decision.
Eighty-two per cent of the included articles were published
between 2012 and 2020. Of these, 62% were published between
2015 and 2020. Twenty-four of these papers related specifically
to cell therapy while 11 pertained to gene therapy. Five of
the included studies were conducted in the UK12–16, eight in
the USA17–24, six in Canada25–30, two were conducted in
Australia31,32 and one each from Belgium33, China34, Germany35,
Hungary36, Ireland37, Japan38, Korea39, South Korea40 and
Sweden41. One study included multiple countries across Eur-
ope42, three studies were set in Canada and USA43–45 and one
included Europe, USA and Canada46. Supplementary Table 4
provides further details on the characteristics of these studies and
their critical appraisal. Below, we present the four themes gen-
erated from the narrative synthesis of the study findings. Table 1
details key areas for the patient and public education based on the
findings of this review.
Knowledge and understanding of cell and gene therapies. The
studies reported varying levels of patient knowledge and under-
standing of cell and gene therapies13,19,23,31,33,40,41. Studies in
patients with ischaemic stroke, cystic fibrosis and sickle cell
anaemia found that they had limited prior knowledge of cell and
gene therapy13,23,40,41. Participants with human immunodefi-
ciency virus (HIV), in a study, were aware of the potential
application of gene therapy in conditions like Parkinson’s disease,
yet few knew about its potential use in HIV/AIDS treatment19. A
study conducted with a few young adults reported high levels of
awareness of gene therapy35. The male gender and higher edu-
cational degrees were also associated with a higher level of
knowledge on cell therapies in a mixed population of cancer
patients and members of the public33.
In general, patients were uncertain about the sources of cells,
the use of viral vectors and their likelihood of transmitting
infection, and the risks of concomitant chemotherapy19,23. They
were also unclear about the distinction between the use of the
therapies in research and their clinical application as licensed
therapies36.
Patients often struggled to understand the reason for the
prolonged time interval between scientific discoveries and the
commencement of trials and subsequent regulatory approvals.
They often worried that the time frames may not match their own
limited therapeutic window especially as their conditions
deteriorated21,25.
There were “therapeutic misconceptions” among patients where
they confused the goals of research and those of clinical care25.
Many also appeared to confuse the goals of various phases of
clinical trials and did not realise that the main focus of phase 1
trials is to establish safety and not demonstrate therapeutic benefit.
Regardless of their level of knowledge, patients generally
expressed a desire for more information and clarity19,21,23,32,43.
However, some patients were of the opinion that they did not
need to fully understand the science behind these therapies,
trusting the opinions of the healthcare providers on efficacy and
safety13.
The studies with members of the public focused on opinions
rather than actual knowledge of cell and gene therapy. However,
based on some of the studies, it could be inferred that just like
patients, the public do not perceive themselves well informed on
the subject and desire more information34,38. A study also
reported differences in the type of information the public desire
and that which is of interest to the scientific community38. For
instance, members of the public were more interested in the cost
of therapies and measures for safety38.
Acceptance of cell and gene therapies. Acceptance of cell and
gene therapies varied among patients15,17,19,21,23,31,41,43 but
generally increased after the provision of information19,21,23,41.
There was a tendency for respondents who were more accepting
to focus on potential benefits that may be gained overtime or the
possibility that new treatments may become available before the
potential benefit from gene therapy ended21. Male gender, older
respondents, higher education, longer duration and greater
severity of the underlying condition and greater risk of death were
associated with greater acceptance of stem-cell research and the
perception that it is beneficial for the society and morally
acceptable15,21,23,33,39. There were also indications that older
patients may have altruistic motivations for participating in gene
therapy trials23. One study explored the issue of cost by asking
stroke patients how much they were willing to pay for cell ther-
apy. The majority (67%) felt a reasonable price would be under
US$1000 at a time when the actual cost of treatment was esti-
mated as ranging from US$5000 to $39,50040.
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The source of stem cells influenced attitudes towards cell
therapies and was at times a source of confusion among patients19.
There were very limited reports of the explorations of ethics in the
articles focused on patient and carer perspectives. Some partici-
pants in the study by Wright et al. commented that more efforts
should be made to prevent diseases rather than finding a cure15.
The use of the HIV vector in gene therapy was of concern to
participants in the study by Strong et al.23. Whilst it was uncertain
that the provision of clarification about the use of the HIV vector
changed patients’ opinion of gene therapy, they suggested that
educational materials should emphasise that the virus is not
present in the therapy otherwise patients may be put off23.
Studies involving the public generally reported support for cell
and gene therapy research16–18,24,29,30,34,38,42,45,46 with most
participants in some studies confirming that they would be happy
to donate their tissue for research14,17,22,38. A study showed that in
the West, support for stem-cell research might vary by region with
the highest level found among Canadians, then Americans and
finally Europeans46. Public support for cell and gene therapies was
highest for potentially fatal or severely debilitating diseases34,45.
Similar to the patient findings, men and individuals with higher
education were more likely to support cell and gene therapy18,42.
In contrast, older people were found to be less supportive42.
Public opinions about the ethics of cell and gene therapies
were explored by a number of studies18,28,30,42,45. These
discussions focused on research into the use of embryonic
cells and gene editing for non-therapeutic purposes. Majority of
the studies reported low public acceptance for these types of cell
and gene research18,30,42,45. The use of embryonic cells was
generally perceived as amoral, ‘crossing the line’ and ‘playing
God’18,30,42,45. There were concerns that gene editing for human
enhancement may threaten genetic diversity in the long term30.
There were also concerns that if cell and gene therapies become
freely available, governments may interfere with the individual/
parent’s right to choose and make it mandatory to undergo such
treatments30.
Among individuals that supported the use of gene editing for
enhancement purposes, the highest levels of support were for
increasing life span, improving intelligence, and improving strength
and fitness45. A neutral response to the use of gene editing for
enhancement was reported in the Chinese population34. Indivi-
duals with children were reported to be more likely to be in
support34. Interestingly, about 60% of the participants in a study
expressed support for the use of embryonic stem cells with the
proviso that strict government regulations are in place28. The
influence of religion on public beliefs were generally inconclusive45.
There were discussions about the cost of treatment and funding
for cell and gene research. The high cost of treatment was a
concern to the Chinese public34 and a study of online posts
reflected public concerns over limited availability and central
funding of stem-cell therapy44. In fact, a US poll reported a
consistent trend suggesting public support for the easing of
government restrictions on stem-cell research funding20. Some
participants expressed support for greater scientific freedom
which could lead to therapeutic discoveries. On the other hand,
some feared scientific malpractices may occur if restrictions were
relaxed17,28 while others were worried about the adequacy of
regulatory approval system.42
Understanding of risk and benefits of therapy. In a number of
studies, patients tended to overestimate the benefits of therapy,
Table 1 Key areas for patients and public education.
Risk of infection from donated genes/cells, viral vectors
and the sources of cells
These important topics require the provision of accurate and adequate information as a
number of the included studies indicated that the perceived risks of infection and the source
of stem cells might influence patient and public attitudes towards cell and gene therapies.
These attitudes may in turn influence political decisions; determine the success of trial
enrolment and retention as well as the subsequent adoption of cell and gene therapies.
Expectations of benefit from therapy and understanding
of treatment risk
Overestimation of therapeutic benefits or underestimate risks of harm also known as
“therapeutic misestimation” may be addressed by ensuring that the information provided is
clear, balanced and unbiased. Especially as media discourse tend to focus on sensational
aspects of cell and gene therapy and online media sources, in particular, are often less critical
in their reports44 thus potentially fuelling therapeutic misestimation. The findings on conflict
burden experienced by carers indicate the need to be aware of the complex and at times,
conflicting caring and interpersonal contexts which may influence the decision-making
process.
Engagement with clinicians The finding that some patients avoid discussing their interest in cell and gene therapies with
their physicians43 may signify that some already have the notion that physicians may
downplay or dismiss potential benefits. Therefore, whilst managing unrealistic expectations is
important, it is also essential that the potential benefits are not downplayed as this may risk
eroding the trust patients and members of the public have in the healthcare system.
Time frames for translation of products from research to
clinical application
Overoptimistic messages about time frames may not only lead to disappointment but also
undermine trust in researchers and threaten funding support25. Information on the processes
involved in the translation of research to the clinical application should be provided in lay
terms. This may facilitate a reassessment of patient expectations in terms of participation in
clinical trials and the availability of therapies in a clinical setting in light of patient-specific
therapeutic windows.
Clinical research versus routine clinical application There is a need for patients and members of the public to understand the distinction between
clinical trials and routine clinical application. Clarifications are also required about the aims of
each clinical trial phase as the review findings suggest that there are considerable therapeutic
misconceptions among patients and members of the public.
Unlicensed versus licensed indications for cell and gene
therapies
Although not the focus of our review, it is important that patients are aware of the health risks
of “stem-cell tourism”, which often involve treatment with unlicensed therapies. Patients
rarely see the warnings on unproven therapies posted on regulatory websites. Such
information needs to be provided through a combination of channels patients use and trust
including their physicians7.
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particularly around whether the therapies would be disease lim-
iting or disease reversing12,21,33,39,40. Some studies reported that
patients were so eager to gain access to therapy, that they
expressed minimal consideration for the potential side effects and
had unrealistic expectations around the timescales for the avail-
ability of actual therapeutic options21,25,33,35,39. These patients
tended to be male, older respondents with longer duration and
greater severity of underlying condition21,33,39,40.
Conversely, some patients were worried about the considerable
uncertainty around the benefit that may be derived given the
potential risks of gene therapy21,23. A study reported that parents
of younger children, in particular, expressed more concerns about
the benefit/risk balance21. However, the majority of the parents in
this study confirmed that their tolerance for risk would increase
as their children grew older, the child’s health deteriorates, and
treatment options become more limited21. Some adults with poor
health status also shared similar views21. There were also
concerns about the use of chemotherapy in the gene therapy23.
Given the association of chemotherapy with cancer treatment and
the risk of developing cancer, patients were worried the side
effects of chemotherapy would be taxing on their bodies and they
could be trading their current illness for cancer23. The
participants were of the opinion that more information about
potential benefits, risks and logistical requirements of participat-
ing in trials is required to make an informed assessment of benefit
versus risk23.
A study reported that partners and carers of patients with
stroke often experienced ‘conflict burden’12. They strived to
balance their concerns about risks with the hope that their loved
ones’ condition would improve by participating in clinical trials12.
The carers reported a sense of guilt for holding reservations and
not being as supportive as they felt they ought to when the
patients nursed high hopes of recovery. In addition, there were
concerns that patients might have difficulties understanding trial
information, due to cognitive impairments, during the acute post-
stroke period, leading to poor decisions12.
Information needs and current sources of information. Patients
frequently indicated a desire for more information regardless of
their gender, age or educational status19,23,32,43. Some patients
suggested that educational materials should report results from
large, long-term studies and explicitly report the risks and side
effects observed in these studies23. They also expressed a need for
more information on the eligibility criteria for studies and more
personalised information21,23.
Television was identified as the major source of information on
cell and gene therapy for patients, along with newspapers and
magazines, the radio, clinicians, friends and colleagues40,41.
However, the study by Aked et al., reported that patients
perceived physicians as the most reliable source of information41.
It was interesting to note that despite the view that information
obtained from physicians was more trustworthy, many patients
may not discuss cell and gene therapy with their physicians43.
Patients identified facilitators of trusted communications between
themselves and physicians to be caring, attentive and positive
physician attitudes and the patients’ positive perceptions of
physician knowledge43. Some participants in search of guidance
expressed frustration at the attitude of professionals who adopted
a non-committal stance or provided inconsistent and conflicting
advice32.
Public trust in the information provided by scientists, medical
researchers and ethicists was reported to be substantially higher
than trust in any other social group including the media, religious
leaders and the US political system20. There was also distrust of
regulatory authorities in Central and Eastern Europe42. Media
coverage was often considered sensational, mostly reporting
specific breakthroughs or safety incidents26,36. Articles on
embryonic stem cells dominated newspaper reports on stem-
cell therapy for over a decade (1998–2010) and often positioned
induced pluripotent stem cells as an ‘ethical’ alternative when
these were discovered in 200726. There was a tendency for online
media coverage to omit information about the existence or lack of
evidence to support cell and gene therapies and the potential
risks44.
Hypothetical relationships between the themes. Figure 1 shows
a hypothetical model of the inter-relationships between the var-
ious themes and sub-themes identified in our review. Based on
our findings we hypothesise that the acceptance of cell and gene
therapy by patients and the public is influenced by their knowl-
edge and understanding of these therapies; their understanding of
the potential risks and benefits; and concerns which may be
procedural, ethical or religious. Their knowledge and under-
standing of the risks and benefits are in turn influenced by the
information they receive from various sources and its trust-
worthiness. Whilst our review also found relationships between
the acceptance of cell and gene therapies and issues such as the
use of chemotherapy and viral vectors in gene therapy proce-
dure23, and beliefs; it is possible that other relationships exist
which were not captured by the included studies.
Critical appraisal. Response rates: Of the 25 publications expec-
ted to report response rates (studies reviewing or re-analysing
data may not have access to such data) only 10 (40%) did.
Reported response rates were high (>75%) in five
studies15,31,40,41,47, moderate in (50–60%) in two23,35 and low in
three studies (<30%)13,29,38.
Sample sizes: The sample size used in a study has an impact on
the precision of its findings. Sample size requirements were
expected to vary depending on the study methods. A few studies
reported sample sizes smaller than the recommendations for
surveys15,41 and qualitative research13,21,27,35. However, this
should be interpreted with caution as three of the qualitative
studies were conducted with patients with rare diseases (cystic
fibrosis13, RPE65 deficiency35 and Duchenne muscular dystro-
phy21). These studies often struggle with patient recruitment due
to very small patient populations.
Participant characteristics: Information on participant char-
acteristics assist with the determination of potential recruitment
bias and the generalisability of the findings. There was a wide
variation in the level of reporting of participant characteristics.
Understandably, studies relating to the media, re-analysis of poll
data and rare diseases might not be able to report this in detail. In
addition, studies in rare diseases often provide limited informa-
tion on patient characteristics in order to preserve patient
anonymity.
Study methods: Various issues were identified in the methods
used by the authors. For instance, Benjaminy et al.25 and Peay
et al.21 recruited patients via patient advocacy groups which
might indicate potential recruitment bias. However, Peay et al.
argued that the advocacy group reflected the patient population
and trial participants would most likely be recruited through
these organisations.
Funding and competing interests: This was considered an
important indicator of study quality as it assists with the
assessment of the potential influence of the funder on the work
and the validity of study findings. The source of funding was
reported by 83% of the publications. Majority of which were non-
pharmaceutical. Most of the publications indicated that funders
had no role in the conduct of the studies. However, Peay et al.21
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declared that although funders were not involved in data
collection and analysis, they were involved in the interpretation
and generation of conclusions. It was impossible to assess to what
extent the funder influenced these aspects of the work. Finally,
only 60% of the articles provided an author statement of
competing interests. Further details of the critical appraisal of
the included studies can be found in Supplementary Table 4.
Discussion
Acceptance of cell and gene therapies varied among patients but
generally increased after the provision of information. Male
gender, older respondents, higher education, longer duration and
greater severity of the underlying condition and greater risk of
death tended to be associated with greater acceptance of stem-cell
research among patients. Members of the public generally
expressed acceptance of cell and gene therapy with some geo-
graphical variation. A number of the studies reported that par-
ticipants frequently indicated a desire for more information
regardless of their gender, age or educational status. They were
generally of the opinion that more information about potential
benefits and risks of participating in trials is required to make an
informed assessment of benefit versus risk. Therapeutic mis-
conceptions and misestimations were common among patients
and members of the public. Whilst physicians were generally
regarded as the most trustworthy source of information by
patients, some never discussed cell and gene therapies with their
physician while some expressed frustration at the ambivalence of
their physician. A few studies explored public trust in information
sources of cell therapies. Whilst medical professionals and sci-
entists again ranked highest as the most trustworthy, politicians
and governmental institutions were among the lowest ranking.
Our review found that there are ongoing debates globally on the
ethics of research into and the use of these therapies. These
debates were especially strident when research involving the use
of embryonic cells and gene editing was discussed. The issue of
ethics was linked to equity in access to treatment, allocation of
government funding to support research into cell and gene
therapies and reimbursement for products available to treat
patients.
We compared our findings to those from oncology trials where
traditional modalities of chemotherapy and radiotherapy are
used. The issue of therapeutic misconception among some
patients as highlighted in our review seemed to also occur in
these settings as a study reported that only 33% of respondents
were actually clear about the purpose of phase 1 oncology trials
and 85% decide to participate in phase 1 trials expecting sig-
nificant therapeutic benefits48. Similar to our review, some
patients with advanced cancer were found to overestimate not
only durability but also the chance of tumour response, symptom
palliation and survival benefit49. The enthusiasm of other stake-
holders, with various personal goals, such as researchers, politi-
cians and funders in promoting optimistic timelines often conceal
the fact that the process of translating scientific breakthroughs to
clinical applications takes time and may further compound the
issue of therapeutic overestimation among patients and members
of the public.
Although public opinions on gene editing in babies were not
the focus of our study, there were references to it by members of
the public. We, therefore, compared our findings with the results
of the polls conducted by Stat and Harvard T.H. Chan School of
Public Health and the Pew Research Center on the subject50,51.
There were broad similarities in public views on issues such as a
general lack of support for gene editing to reduce the risk of
developing serious diseases and very low support for human
enhancement purposes52. The issue of federal funding for gene
therapy research received a high level of support across the polls
with a significant number of respondents (44%) in the STAT-
Harvard poll supporting federal government funding of gene
editing in babies to reduce their risk of developing serious dis-
eases50. Another interesting finding in the STAT-Harvard poll
was that 53% of respondents felt scientists and physicians should
make the decision on gene editing. Only 9% felt it should be up to
the government and policymakers to decide50. These reports echo
Knowledge and
understanding
























Fig. 1 Hypothetical model of thematic relationships based on review findings. Arrows indicate hypothetical unidirectional relationships. Double arrows
indicate hypothetical bidirectional relationships.
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our finding that members of the public tended to trust scientists
and physicians significantly more than politicians and govern-
mental organisations. The implication of this finding is that
physicians and scientists are best placed to provide accurate
information that will be trusted by patients and the public. It is
therefore essential that they are actively engaged in the entire
process of developing cell and gene therapies. However, these
professionals need to be aware of the reputational risks involved
and must be transparent about potential conflicts of interests.
Comparing the views and opinions reported in the included
articles published earlier to those expressed in the more recent
ones, there were no radical differences in opinions and it
appeared that whilst the field of cell and gene therapy is making
rapid scientific advances, patient and public perceptions are not
changing as fast. This observation was supported by the report by
researchers at Pew Research Center that the findings in their
2018 survey on public attitudes towards genetic editing were
consistent with findings from their 2014 and 2016 surveys51.
There is a possibility, however, that public opinion (and the
influence of patient advocacy organisations) over time, whether
accurate or not, has influenced political position on stem-cell
therapy which in turn has influenced policy, research funding and
regulation. For instance, the decision by President Obama to
expand federal funding for embryonic stem-cell research in 2009
was linked to the consistent trend in the Gallup polls which
showed that majority of American respondents would like the
government to ease restrictions on stem-cell research funding20.
It is worth noting that the President himself cited public support
as a factor for making the decision53. It is, therefore, essential that
up-to-date and accurate information be provided to patients and
members of the public in the first place given their potential
influence on political decisions. The perceptions and support of
patients and members of the public have been shown to be critical
for the adoption of cell therapies by the healthcare sector and a
lack of such support may significantly hamper development and
adoption54. This further underscores the need to assess existing
opinions among patients and members of the public and then
develop appropriate and trustworthy strategies to correct mis-
conceptions and provide unbiased current information.
The mistrust of the information provided by the government
may be an extension of the general mistrust of political systems or
a perception that governmental position is often swayed by party
politics and not entirely dependent on scientific facts even though
as shown earlier public opinion might be a strong influence itself.
It is possible that an awareness of this public mistrust led to the
UK government including a statement about trust in its recent
White Paper on the regulation of new technologies “… We need
to build trust and enable both consumers to have confidence in
innovations and businesses to have confidence in our stable and
proportionate regulatory system”55.
Whilst the media was ranked low in terms of trustworthiness,
its often over-optimistic and unbalanced portrayals of the
potential benefits of cell and gene therapy undoubtedly influence
the perceptions of patients and members of the public and fuel
therapeutic overestimation56–58. It was interesting to find that
whilst social media has often been considered as the most popular
source of information in recent years, a number of patients still
considered traditional media such as the television as their pri-
mary source of information on cell and gene therapy40,41. Aked
et al.41 reported that most of the respondents had more than one
source of information and we suspect that this would be the case
for most individuals.
It was proposed by Allum et al.46 that at least two key
dimensions - moral concerns and beliefs about benefits, frame
public views on stem-cell research. We observed from our review
of the literature, that whilst there was a tendency for members of
the public to consider and express their opinions about the ethics
of cell and gene therapy, this was less frequently raised by
patients. This might be due in part to the line of questioning by
interviewers. However, we hypothesise that patient views are
mostly framed by the potential risks and benefits of cell and gene
therapy (i.e. the risk-benefit ratio) with ethical concerns carrying
less weight in the discourse. It is essential that this potential
difference in how issues are prioritised by both groups is con-
sidered and guides the design of any educational interventions.
This also shows the importance of tailoring any educational
intervention to the needs and concerns of the particular audience.
Patients and members of the public are generally unaware of
the timescales and challenges manufacturers face developing cell
therapies; obtaining regulatory approvals; scaling up production
utilises costly technological resources to ensure the cells remain
potent throughout the production process and storing and deli-
vering the cells to the patient and physician in a viable and
functional condition54. Developing cell and gene therapies is a
costly venture and securing reasonable reimbursement is an
important post-market challenge54. Reimbursement needs are at
a level higher than the cost of production otherwise the venture is
not viable. The question about whether the individual or the
government should pay for the therapy is central to this issue. If
this falls to individual patients, a significant number of patients
will be unable to purchase such expensive therapies leading to
inequity in access. It has to be said that some patients already pay
for their treatment sometimes travelling abroad to obtain thera-
pies unlicensed in their home countries, the so-called ‘stem-cell
tourism’. In the US, due to gaps in regulation, a number of bio-
technology companies were reported to operate on a pay-to-
participate basis and require patients to pay before they were
enroled to clinical studies22. The most equitable scenario is
government funding but this in the long term may be uncertain as
funding policies may change. It is, therefore, no surprise that
many biotechnology companies have crashed and burned over
the years54.
We did not identify any studies that examined the experiences
of people who have received cell or gene therapies. There is,
therefore, a need to capture the experiences of such patients in
future to improve the evidence base. As therapies start to be
considered by health providers such as the NHS and US Medi-
care/Medicaid, which place value on including the perspectives of
patients, such information may start to become more widely
available. None of the studies specifically considered patient views
on reimbursement, prioritisation or geographical variation in the
provision of cell and gene therapies. Future studies need to
address these issues in depth. The role of the media in infor-
mation provision, especially with the increasing use of social
media, needs to be explored further. The need for a balanced
presentation of information is important. Strategies to ensure that
the media serves as a trustworthy source of information need to
be developed.
We found fewer articles on gene therapy compared to those on
cell therapy. Whilst this might mean that our review does not
completely capture patient and public views of gene therapy, we
believe it is useful to report what we found. This imbalance in the
number of articles retrieved highlights the fact that more
research on perspectives of gene therapy is needed. This study
relied on the information provided by the included publications,
which were sometimes limited in detail and quality. Questions
posed to participants were framed in different ways (open-ended
and or closed-ended). For instance, the survey studies employed
close-ended questions that do not reflect emergent opinions or
reflect participant-driven concerns. They have also been reported
to possess low validity and carry the risk of producing framing
effects. For example, the act of asking whether an issue is of
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ethical concern may imply that it is30. It was impossible for us to
assess or measure the effects of these methodological issues based
on the information reported by the authors. In addition, virtually
all the studies reported providing participants with information
sheets and/or verbal information prior to obtaining informed
consent. It is impossible for us to ascertain how much infor-
mation about cell and gene therapy was provided, and to what
degree this influenced participants’ responses during the studies.
The included studies were of variable quality based on our cri-
tical appraisal with methodological issues the most prevalent.
However, it is possible that some of this is due to a reporting
approach where the provision of details on results and its
interpretation in the discussion sections is prioritised over pro-
viding essential details on methodology. The studies included in
this review utilised a variety of methods including interviews,
focus groups and surveys to elicit patient and public views. There
was an absence of papers using consensus methods in the
selected studies. Modified Delphi technique, nominal group
technique or other consensus-based methods may be used to
reach consensus on priority areas for education and information
provision, ideally through discussion with other key stakeholders
such as clinicians, ethicists, regulators, industry and policy-
makers. For those interested in valuing patient/public preference
for alternative therapies (e.g. the use of highly expensive but
potentially curative treatments for a limited number of patients
versus cheaper but non-curative treatments for a larger number
of patients) there are specific health economic techniques such as
stated preference methods, which could be used. These techni-
ques, however, are time-consuming and resource-intensive. This
review highlights the need for high-quality studies exploring
patient and public opinions of cell and gene therapy. We
recommend that future studies follow current methodological
guidance such as the consolidated criteria for reporting qualita-
tive research59 and the guideline for survey research60, which can
be found on the Equator Network website.
Although not the focus of the present study, PPI in research is
an important and vital component of patient-centred care and
clinical research. PPI has been defined as “…research being car-
ried out ‘with’ or ‘by’ patients and members of the public rather
than ‘to’, ‘about’ or ‘for’ them”61. PPI has been recognised as a
vital activity that may facilitate the acceptability, relevance,
timeliness and quality of research62–64. PPI may occur at an
organisational level where individual patients and members of the
public are involved in the development of cell and gene therapy
by providing feedback and collaborating at all stages of clinical
trials, dissemination of trial results and finally involvement in
decisions regarding licensing reimbursement of cell and gene
therapies. It could also occur at a higher level where patient
organisations, exert advocacy influence. For instance, ensuring
that research into stem-cell therapies receives appropriate funding
from the government. We noted minimal reports of PPI in the
included studies and recommend that patients should be involved
in the co-design of future studies. The expectation is that the
findings of this review may also inform the design of future PPI
initiatives in the field of cell and gene therapy.
Cell and gene therapies have the potential to change the
treatment of diseases, which currently have limited treatment
options. However, there are associated risks to patients and
complex challenges translating these scientific breakthroughs into
clinical applications. Patient and public perceptions could play a
vital role in the development of therapies and influence their
subsequent uptake. Patients and carers need to be provided
adequate and accurate information which may influence their
perception and acceptance of cell and gene therapy. They need to
be provided information on the potential benefits that may be
gained from cell and gene therapy and the risks involved so that
they can make informed decisions about participation in clinical
trials and licensed routine administration. Working with patient
partners in the co-design of further research and or educational
resources is central to addressing the issues we have highlighted.
Methods
The protocol for this review was registered with PROSPERO (Ref.:
CRD42019131831). The study was reported according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist65.
Search strategy. We adapted the Scottish Intercollegiate Guidelines Network
(SIGN) Patient Issues filter to search for relevant research studies (https://www.
sign.ac.uk/search-filters.html) (Supplementary Table 2). There were no language or





● Cochrane Database of Systematic Reviews
● DARE
● HTA
● Cochrane Central Register of Controlled Trials, Current Controlled Trials and
the PROSPERO databases were searched to identify any ongoing studies,
reviews and grey literature as recommended by Blackhall and Ker66.
The searches were conducted between 4th December 2018 and 5th April 2019
and restricted to studies published from the 1st January 2009 onwards. The cut-off
date of 2009 was selected because the EU legislation on ATMPs (Regulation (EC)
No 1394/2007) came into force at the end of 2008 and the EU ATMP definitions
were updated in 2009 (Commission Directive 2009/120/EC). In addition, the first
successful phase III gene therapy clinical trial in the EU was reported in 2009 thus
signalling significant progress in the development of cell and gene therapy for
clinical application1. We believe this date range would ensure that we capture the
most recent literature whilst minimising the chance of missing any relevant studies.
The search string for Medline was adapted for the other databases (Supplementary
Table 2). Following peer-review, we also searched (without date restrictions) the
Pew Research Center database using the ‘science’ filter (https://www.pewresearch.
org/) and the entire Harvard Opinion Research Programme database (https://www.
hsph.harvard.edu/horp/) to ensure that we captured any other relevant grey
literature.
Inclusion criteria.
– Qualitative and or quantitative studies focusing on cell and somatic gene
therapies in the clinical application or being currently considered within
clinical trials.
– Studies with patients who have received, or may be eligible to receive cell or
gene therapy; family carers; or members of the general public.
– Studies exploring or evaluating levels of knowledge, understanding and
awareness; expectations or hopes; experiences of treatment; views, attitudes
and perspectives on cell and gene therapies.
Exclusion criteria.
– Narrative reviews, commentaries, opinion pieces and letters that do not report
primary findings.
– Studies focused exclusively on the perspectives of healthcare professionals and
or scientists.
– Studies focused entirely on embryonic stem-cell therapy or germline gene
therapy (due to the complex legal and ethical issues associated with these
therapies).
– Studies reporting hematopoietic stem-cell transplants (as this type of
treatment is no longer novel)67.
Selection process. Search records were exported to EndNote. An experienced
reviewer (K.M.) screened all the titles and abstracts. To check that the eligibility
criteria had been consistently applied, another experienced reviewer (O.L.A.)
independently screened 20% of the titles and abstracts. Full-text articles were
retrieved for studies potentially eligible for inclusion and the same reviewers
independently evaluated all articles. Reasons for exclusion were documented. Hand
searching of reference lists and citation searching of the included articles was
conducted. The reviewers through discussion resolved discrepancies at all stages.
Data extraction. A data extraction form was designed and piloted by K.M. and
O.L.A. on a few studies before commencing full data extraction (Supplementary
Table 3). Data extracted included: (i) participant group studied and where available
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their age, gender, socioeconomic status and level of education; (ii) number of
participants; (iii) current health of participants; (iv) type of therapy; (v) standard
care; (vi) healthcare setting; (vii) study design; (viii) results, (ix) study quality and
(x) author conclusions. The included papers were split between K.M., O.L.A., L.E.
and S.M. for extraction. All extracted data were double-checked by another indi-
vidual among the four to ensure accuracy and consistency.
Critical appraisal. A formal quality assessment of included articles using a
checklist was not conducted because the studies employed a variety of quantitative
and qualitative methods which produced results that were not directly comparable.
Therefore, we critically appraised each article using five quality indicators extracted
using the data extraction form: (i) response rate, (ii) sample size, (iii) participant
characteristics, (iv) study methods and (iv) funding and competing interests) as
reported by Kirkby et al.68.
Synthesis of studies. Given the high level of heterogeneity across the included
studies, we did not conduct a meta-analysis of quantitative studies or a meta-
synthesis of the qualitative studies. Instead, we undertook a narrative synthesis
using the method described by Popay et al.69. This entailed: (i) A descriptive
summary of the information extracted on study characteristics and critical
appraisal. (ii) The exploration of associations between study characteristics and
reported findings within individual studies, as well as across studies. (iii) Discus-
sion of the findings and provision of recommendations for future research and
clinical practice.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that all data generated or analysed during this study are included in
this published article and in Supplementary Table 4. All the publications included in this
systematic review are available through open access or personal or institutional journal
subscriptions.
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